CSMG Technologies Announces David Colvin to Become Director of Worldwide Sales and General Manager of GSM Medical Division of Its Subsidiary Live Tissue Connect, Inc.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc., (OTCBB: CTUM), a technology management company, announced that its subsidiary, Live Tissue Connect ("LTC"), to hire David Colvin as Director of Worldwide Sales and Marketing.

Don Robbins, President and CEO of CSMG Technologies, said, "We are continuing to attract what we believe to be a top LTC management team that is working in coordination with our quality elecrtrosurgery generator and hand instrument designers and manufacturers, as we begin to implement worldwide technology commercialization and sales."

Frank D'Amelio, President of Live Tissue Connect, Inc. said, "We are very pleased that David is joining LTC as its Sales and Marketing Director, and will also be heading up our GSM Medical Division. David has had a successful career in sales and marketing of medical devices with four other advanced technology companies. Attracting a leader with this level of experience, and a wide skill set, will be instrumental to our success. Since 2007, David has made significant contributions toward our FDA clearance efforts, gaining our CE Mark, developing our business strategy, clinical testing, and is presently setting up a worldwide distribution network."

In addition to his position as LTC's Director of Worldwide Sales and Marketing, Mr. Colvin has been appointed General Manager of Live Tissue Connect's GSM Medical Division. This division is focused on marketing LTC's innovative sealing and cutting technology into the General Surgery and Gynecology arenas.

Mr. Colvin added, "I am pleased to accept this position to commercialize a revolutionary medical technology and work with a group of medical device veterans that have the experience, skills and contacts to what I believe adds to the success of LTC. The efficacy demonstrated in clinical applications where our tissue welding technology has been utilized is impressive, and the number and variety of potential human applications is staggering. The opportunity to bring to market an entire family of bipolar RF sealer, cutters and staple-less staplers, that have been in clinical use in Eastern Europe is quite unique."

Mr. Colvin has extensive sales and marketing experience in the medical device industry. He has earned numerous sales awards selling devices to the Orthopaedic, Gynecology, General Surgery, and Urology markets and has held senior marketing and sales management positions with Bristol-Myers Squibb, W.L. Gore & Associates, Circon Corporation and Urologix.

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 44 patents and patent applications in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: http://www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.